XML 20 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727
Acquisition of Totipotent RX (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Feb. 18, 2014
USD ($)
Subsidiary
Mar. 31, 2014
USD ($)
$ / shares
Mar. 31, 2014
USD ($)
$ / shares
Mar. 31, 2015
USD ($)
Jun. 30, 2014
USD ($)
Fair value of liabilities assumed [Abstract]          
Goodwill       $ 13,195 $ 13,254
TotipotentRX Corporation [Member]          
Business Acquisition [Line Items]          
Number of wholly owned subsidiaries | Subsidiary 2        
Acquisition related costs   $ 484 $ 1,725    
Business acquisition carrying amount of equipment acquired $ 59        
Purchase Price [Abstract]          
ThermoGenesis common shares and warrants 27,287        
Fair value of assets acquired [Abstract]          
Cash 351        
Receivables 171        
Inventories 191        
Clinical protocols 19,870        
Other intangible assets 2,187        
Equipment 384        
Other assets 132        
Total assets 23,286        
Fair value of liabilities assumed [Abstract]          
Accounts payable 514        
Related party notes payable 337        
Deferred tax liability 8,048        
Other liabilities 295        
Total liabilities 9,194        
Net assets acquired 14,092        
Goodwill $ 13,195        
Supplemental Pro Forma Data [Abstract]          
Net revenues   4,099 12,738    
Net loss   $ (1,702) $ (5,139)    
Basic and diluted net loss per common share (in dollars per share) | $ / shares   $ (0.04) $ (0.16)    
TotipotentRX Corporation [Member] | Nonrecurring Merger-related Costs [Member]          
Supplemental Pro Forma Data [Abstract]          
Nonrecurring expenses directly attributable to merger   $ 531 $ 1,933